Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.86 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | APLNR | P35414 | 4/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL7751433 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL6448301 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| SCHEMBL21109135 | 0.99 | GNRHR (0.84) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | CYP21A2, CYP17A1, NR5A1 | GNRHR 20/4885ABCC2 4645/4885PTGS1 2030/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | GNRHR 20/4885ABCC2 4645/4885PTGS1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.